MTRR rs1532268 polymorphism and gastric cancer risk: evidence from a meta-analysis

J Int Med Res. 2022 May;50(5):3000605221097486. doi: 10.1177/03000605221097486.

Abstract

Objective: The methionine synthase reductase (MTRR) gene encodes the MTRR enzyme involved in the metabolic pathway of homocysteine. Several studies investigated the effect of the MTRR rs1532268 gene polymorphism on the risk of gastric cancer (GC), but the results have been inconsistent.

Methods: We performed a comprehensive and systematic search of PubMed, Google Scholar, MEDLINE, Science Direct, Scopus, CNKI, and Web of Science. Five studies were included in this meta-analysis to determine whether MTRR rs1532268 polymorphism contributes to the risk of GC.

Results: Pooled data indicated that the MTRR rs1532268 polymorphism significantly increased GC risk under the allele comparison model (odds ratio [OR] = 1.14, 95% confidence interval [CI] = 1.01-1.29) and dominant model (OR = 1.14, 95% CI = 1.00-1.30). In the analysis stratified by ethnicity, no relationship was found in Whites or Asians.

Conclusion: Our meta-analysis suggests a positive correlation between MTRR rs1532268 polymorphism and GC development.

Keywords: Methionine synthase reductase; biomarker; gastric cancer; meta-analysis; polymorphism; susceptibility.

Publication types

  • Meta-Analysis

MeSH terms

  • Case-Control Studies
  • Ferredoxin-NADP Reductase
  • Genetic Predisposition to Disease
  • Humans
  • Polymorphism, Single Nucleotide
  • Risk Factors
  • Stomach Neoplasms* / genetics

Substances

  • methionine synthase reductase
  • Ferredoxin-NADP Reductase